Skip to Main Content

Each year, the Food and Drug Administration tracks its progress inspecting pharmaceutical manufacturing facilities and issuing follow-up letters for plants that require significant fixes. But in the most recent fiscal year, there was a significant drop in productivity.

Specifically, the agency sent just 70% of letters that should have gone out to summarize the final regulatory classification for facilities within 90 days of an inspection. And only 48% of regulatory actions were completed within six months for manufacturing plants that had quality control problems that needed to be addressed, according to the report.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment